Description
Generics: Chlorpheniramine Maleate
Dosage Form: Syrup.
Indications:
Chlorpheniramine Maleate is indicated in the following indications-
- Urticaria
- Sensitivity reactions
- Angioneurotic edema
- Vasomotor rhinitis
- Cough
- Common cold
- Motion sickness and
- Other allergic conditions.
Pharmacology:
Antista® (Chlorpheniramine Maleate) is an alkylamine antihistamine. It is one of the most potent H1 blocking agents and is generally eÂective in relatively low doses. Antista ® is not so prone to produce drowsiness, readily absorbed from the gastro-intestinal tract, metabolised in the liver and excreted usually mainly as metabolised in the urine.
Dosage guideline:
Twice daily.
Adult- Usual adult dose is 4 mg every 4-6 hours, maximum 24 mg daily.
Child-
6-12 years: 2 mg every 4-6 hours, maximum 12 mg daily.
2-5 years: 1 mg every 4-6 hours, maximum 6 mg daily.
1-2 years: 1 mg twice daily.
Below 1 year the use of Chlorpheniramine Maleate is not recommended.
Route of administration: Orally.
Interaction:
Chlorphenamine maleate has been reported to be incompatible with calcium chloride, kanamycin sulfate, noradrenaline acid tartrate, pentobarbital sodium, and meglumine adipiodone.
Contraindications:
Chlorpheniramine is contraindicated in patients hypersensitive to this agent, in newborn or premature infants.
Side Effects:
Chlorpheniramine is well-tolerated, but sometimes drowsiness, dizziness, muscular weakness, and gastrointestinal upset may occur.
Pregnancy & Lactation:
This drug should not be used in lactating mother and in pregnancy especially during the first trimester of pregnancy.
Precautions & Warnings:
Chlorpheniramine should be used with caution in patients with glaucoma and prostatic hypertrophy. During therapy with chlorpheniramine, caution should be taken in driving vehicles and operating machinery.
Therapeutic Class:
Sedating Anti-histamine
Storage Conditions:
Store in a cool below at 25°C temperature. Keep in a dry place, away from light and heat. Keep out of the reach of children.
Manufactured by: Square Pharmaceuticals Ltd.
